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Introduction 
Emphysema and interstitial lung disease produce opposing 
effects on lung volumes and spirometry (1). This makes 
lung function difficult to interpret vis-d-vis the severity of 
either condition. While this conundrum is familiar to 
respiratory clinicians, there is little literature on the subject. 
We report a patient with severe stable emphysema (forced 
expiratory volume in 1 set, FEVi 40-50% predicted) whose 
spirometry approached normal when his condition was 
complicated by amiodarone pulmonary toxicity. 
Case Report 
A retired male farmer born in 1920 has had diagnosed 
emphysema for many years. He stopped smoking (40 pack- 
years) in 1976 at the time of an inferior wall myocardial 
infarction. Exertional dyspnoea progressed until he pre- 
sented in 1991 with marked reduction in exercise tolerance 
(75-100 m or one Ilight of stairs), little cough or sputum, 
severe fixed airflow obstruction (FEVi 1.011, 45% of 
predicted), resting oxygen saturation 88% and a chest 
radiograph showing hyperinflation, vascular deficiency with 
numerous bullae and cardiomegaly. He had no clinical 
findings of cardiac failure. He was reluctant to consider 
prednisone; a trial of beclomethasone dipropionate 500 ug 
b.d. resulted in a slight non-significant and unsustained 
improvement in FEVi (1.19 1) and oxygen saturation 
(90%). FEVi declined slowly over 4 years (Table 1) with 
slowly decreasing exercise tolerance. In 1994, home oxygen 
was started following an infective exacerbation leading to 
hospitalization. 
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In October 1995, life-threatening ventricular tachycardia 
with hypotension developed. After stabilization with 
medical treatment, amiodarone was prescribed 200 mg 5 
days a week. Cardiac catherization revealed a left 
ventricular aneurysm, 80% stenosis of the LAD artery 
and complete stenosis of the right coronary artery. 
Furosemide and potassium were added in 1995 and 
lisinopril in 1996. Over 27 months, exercise tolerance was 
stable (50-75 m), SAO~ was stable (92-3% on 2 1 O2 
mini), and FEVi was slightly improved (Table 1). In 
January 1998, a non-life-threatening wide complex tachy- 
cardia (heart rate 140) resolved promptly with intravenous 
lidocaine. Amiodarone was increased to 200 mg daily (a 
40% increase in total dose). 
Progressive worsening of exertional dyspnoea led to 
hospitalization in April 1998, at which time oxygen 
saturation on supplemental oxygen had fallen to 88% 
(arterial blood gas). Lung function showed an approxi- 
mately 30% increase in FEVi and a significant decrease in 
carbon monoxide diffusing capacity. Chest radiograph 
showed patchy, mixed interstitial and airspace disease 
most marked bilaterally in the mid- to upper lung zones. 
There was also parenchymal scarring, architectural distor- 
tion and a moderate decrease in lung volume. These 
findings were gradually progressive since the introduction 
of amiodarone therapy in October 1995, but were acutely 
worse since the most recent radiograph of January 1998 
prior to increase in the amiodarone dose. Left ventricular 
failure was excluded clinically with no clinical response to 
diuretic therapy. 
Amiodarone toxicity was suspected. The patient and his 
family were reluctant to discontinue amiodarone and also 
reluctant to consider either prednisone therapy or an 
implantable defibrillator. One month later, he was extre- 
mely breathless, exercise tolerance was limited to 10 steps, 
the FEVi had further increased and the diffusing capacity 
had further decreased (Table 1). Chest radiograph now 
showed the above-mentioned changes plus ground-glass 
opacification in the left lower lobe suggesting an acute 
alveolitis. 
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TABLE 1. Lung function 
Date 
1991 
1992- 
Oct. 1995 
Nov. 199.5- 
July 1997 
Jan. 
1998 
April 
1998 
May 
1998 
June Sept. 
1998 1998 
FEVdl) 1.02-1.19 0.834~98 0.78-1.15 1.16 1.47 1.70 1.99 1.68 
(% pred) (51) (65) (76) (88) (75) 
FEF2575% (1 set-‘) 0.334.37 0.174.26 0.21&0.36 0.35 0.57 0.94 1.01 0.62 
(% pred) (17) (27) (45) (48) (30) 
FVC (1) 2.4c2.90 2.49-2.93 2.363.32 2.88 2.79 2.57 3.19 3.15 
(% pred) (83) (81) (75) (92) (92) 
TLC (1) nd. 5.7 4.8 nd. 
(% pred) (“d:, ?;3: td:, (:o:, 
DLCO n.d. 5.9-6.5 6.0-7-O nd. 4.4 3.4 6.3 5.2 
(ml min - ’ mm Hg-‘) 
(Oh pred) (17) (14) (25) (20) 
Amiodarone 0 0 1000 1400 1400 1400 0 0 
(mg) week-’ Start Nov. 1995 stop 
Prednisone 0 0 0 0 0 0 30 5 
(mg) day-’ Start 
n.d. not determined. 
Amiodarone was discontinued, prednisone 30 mg per day 
started, and exercise tolerance returned to baseline in a few 
days. When reviewed 18 days later, his spirometry had 
nearly normalized (FEVi 88% predicted), diffusing capa- 
city had returned to baseline and the computerized axial 
tomographic scan showed extensive centrilobular emphy- 
sema and marked bullous disease, findings consistent with 
emphysema. In addition, there was moderate parenchymal 
scarring and architectural distortion throughout both 
lungs, as well as left basilar ground-glass pacification and 
some interlobular septal thickening (Fig. 1). Although non- 
specific, these findings can be seen with amiodarone- 
induced pulmonary toxicity. Incidentally, no evidence of 
amiodarone deposition within the liver was noted. 
Recurrent life-threatening ventricular tachycardia led to 
prescription of sotalol and mexilitine. When seen in follow- 
up 2 months later, prednisone had been tapered to 5 mg per 
day, exercise tolerance remained stable and the FEVi had 
begun to decline. Post-bronchodilator spirometry, nitrogen 
wash-out TLC, single breath DLCO, and doses of 
amiodarone and prednisone are shown in Table 1. Selected 
maximal expiratory flow volume curves are shown in Fig. 2. 
Discussion 
It is appreciated that emphysema and interstitial lung 
disease have opposite physiological effects on lung volumes 
and flow rates (1). Airflow obstruction in chronic airflow 
limitation is due to diffuse narrowing of small airways or 
emphysematous loss of elastic recoil, or more often to a 
combination of both. Hyperinflation (increases in TLC, 
FRC and RV) develops secondary to airflow obstruction 
and may be particularly marked when emphysema/loss or 
recoil is prominent. By contrast, interstitial lung disease 
leads to increased elastic recoil with an increased FEVi to 
FVC ratio and small lung volumes. The diffusing capacity is 
typically reduced in both conditions; in emphysema because 
of reduced total surface area of alveolar capillary mem- 
brane and in interstitial disease because of increased 
thickness of the membrane. It seems likely that our patient 
suffered mainly from loss of elastic recoil (emphysema) 
which reversed, approaching normal, with the superimposi- 
tion of amiodarone toxicity. This was associated with a 
severe reduction of the already low DLCO and marked 
exacerbation of breathlessness. Lung compliance (pressure- 
volume) curves would have been of interest in further 
elucidating the physiology. It is likely that the wash-out 
technique underestimated lung volumes compared to whole 
body plethysmography however, it is the policy in our 
laboratory to standardize techniques within a patient so as 
to make serial studies more comparable. 
This patient has a presumptive diagnosis of amiodarone The role of prednisone in the FEVi improvement is 
toxicity complicating his severe chronic emphysema. The uncertain. The FEVi had improved to 76% predicted in 
interstitial process was associated with marked increase in (May 1998) prior to instituting prednisone and discontinu- 
exercise limitation, a further reduction in his diffusing ing amiodarone (Table 1). There was a further improve- 
capacity and an almost doubling of his FEVi from severely ment 18 days later (to 88% predicted). This additional 
reduced to within the normal range. This is an unusual improvement may have been in whole or in part a 
situation and, to our knowledge, has not been prospectively carticosteriod response, probably within the airways as we 
reported. would expect corticosteroid improvement of the interstitial 
FIG. 1 Computerized axial tomographic thin slice (1 mm) cut through upper lungs showing the marked bullous emphysema 
and ‘ground glass’ interstitial changes (see text). 
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FIG. 2. Selected maximum expiratory flow-volume curves with flow (1 set-‘) on the vertical axis and volume (l) on the 
horizontal axis. 
disease should reduce elastic recoil and therefore reduce concomitant chronic airflow limitation/emphysema (2,3). 
FEVr. When emphysema and cryptogenic fibrosing alveolitis are 
Two recent studies stress the difficulties in evaluation of present together, lung volumes tend to be preserved (2,3) 
subjects with cryptogenic fibrosing alveolitis when there is and flow rates (FEVr : FVC ratio) were less likely to be 
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elevated as expected in pulmonary fibrosis (2,3). The value 
of high resolution computerized tomography in assessing 
for the presence of magnitude of interstitial disease has 
been noted (3). In our patient, the advanced emphysema 
made it difficult to appreciate significant interstitial disease 
on the chest radiograph, even though it was suspected. The 
high resolution computerized tomographic scan proved 
very helpful in documenting the ground-glass interstitial 
pattern. The computerized tomographic scan was per- 
formed 18 days after amiodarone was stopped and 
prednisone commenced, at a time when the patient was 
clinically much improved, and we suspect therefore that the 
changes observed may already have been improving. 
In summary, we present the case of a man with severe 
emphysematous chronic airflow limitation complicated by 
at least moderately severe interstitial lung disease, probably 
amiodarone toxicity, whose FEVi and FEV, : FVC ratio 
improved to the normal range from a severely obstructed 
pattern. 
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